Top JAK inhibitor stories in the last month

Healio Rheumatology features the top Janus kinase inhibitor stories posted in the last month.

Tofacitinib seen as safe, effective in patients with ankylosing spondylitis

Tofacitinib — in 5-mg and 10-mg dose regimens twice per day — was effective in patients with ankylosing spondylitis and showed a similar 12-week safety profile to its other indications, according to results of a recently published phase 2 study. Read More.

Long-term extension studies on tofacitinib: Discontinuation most commonly associated with adverse events

WASHINGTON — The median drug survival of tofacitinib was approximately 5 years, with discontinuation most commonly associated with adverse events, such as infections, more than lack of efficacy, according to long-term findings presented at the American College of Rheumatology Annual Meeting. Read More.

Compared with adalimumab, baricitinib demonstrated better efficacy for RA

In patients with rheumatoid arthritis (RA) who had an inadequate response to methotrexate, the oral Janus kinase inhibitor baricitinib demonstrated better efficacy through 52 weeks compared with adalimumab, according to recently published data. Read More.

European Commission approves baricitinib for rheumatoid arthritis

The European Commission has granted marketing authorization to Eli Lilly and Company and Incyte Corporation for baricitinib — as 2-mg and 4-mg once-daily tablets — in the treatment of patients with moderate to severe rheumatoid arthritis who responded inadequately to or who are intolerant to disease-modifying antirheumatic drugs, according to a company press release. Read More.

Tofacitinib showed safety in 3-year, real-world analysis for RA

WASHINGTON — Tofacitinib showed safety comparable to other disease-modifying anti-rheumatic drugs for the treatment of rheumatoid arthritis, according to a real-world, 3-year analysis presented at the American College of Rheumatology Annual Meeting. Read More.